KR101886240B1 - Method for screening drug inducing exercise-mimetic effects - Google Patents

Abstract

The present invention relates to a method for screening a drug for inducing exercise-like effects using an? 1-adrenergic receptor agonist, and a pharmaceutical composition for inducing exercise-like effects containing a drug screened by the above method as an active ingredient. According to the method of the present invention, drugs that cause exercise-like effects in vitro can be screened easily and with high precision. Therefore, drugs screened by the present method can be used for the treatment of diseases (metabolic diseases, heart failure and inflammation) Can be usefully used for prevention / treatment.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for screening drug-

The present invention relates to a method for screening a drug for inducing exercise-like effects using an? 1-adrenergic receptor agonist, and a pharmaceutical composition for inducing exercise-like effects containing a drug screened by the above method as an active ingredient.

Exercise training improves exercise tolerance by activating a remodeling program that causes phenotypic changes in skeletal muscle, and moderate exercise is effective in improving pathological conditions such as metabolic disease or heart disease.

In particular, AMP-activated protein kinase (AMPK), peroxisome proliferator activated receptor (δ), and PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1α) are involved in the phenotypic changes of skeletal muscle It is known as an argument.

AMPK is a heterotrimeric complex consisting of α / β / γ subunits. It is activated by phosphorylation by LKB1 and CaMKK (Ca2 + / calmodulin-dependent kinase kinase), the upper enzymes of AMPK during muscle contraction and exercise. And is a major regulator of cellular / organ metabolism for glucose homeostasis, appetite, and exercise physiology. PPAR-δ plays a key role in transcriptional regulation of skeletal muscle metabolism, PGC-1α is involved in energy metabolism as a regulator of mitochondrial biosynthesis and function, and is involved in transcriptional regulation of genes activated by resistance to skeletal muscle Is an activating factor.

AMPK is known to be able to target several transcription programs at the same time, and these transcriptional programs are regulated by substrates such as PPAR-δ and PGC-1α, resulting in a genetic effect similar to exercise. In this regard, it has been reported that exercise-like drugs targeting the AMPK-PPARδ signaling pathway may be a novel pharmacological strategy for reprogramming muscles for resistance phenotype (Cell 2008, vol.134, pp405-415 ).

In addition, some drugs that promote AMPK activation such as A-769662, metformin, 5-aminoimidazole-4-carboxamide-1-beta-D-lipofuranoside (AICAR) and resveratrol It has been reported to exert a therapeutic effect on heart failure. The protective function of AMPK on cardiomyopathy is to decrease the production of reactive oxygen species in the cytoplasm, inhibit the activity of angiotensin II, phosphorylation of cardiac troponin I, activation of PGC-1α, regulation of eNOS-NAD (P) H oxidase expression, AMPK activation can be directly or indirectly enhanced in myocardial function, as it can be achieved through important functions such as modulation of related receptors and regulation of energy balance and intracardiac signaling.

As such, AMPK activation (phosphorylation) and related factors (PPAR-δ, PGC-1α) induce exercise-like effects such as glucose uptake, energy metabolism homeostasis, and cardiac function enhancement in skeletal muscle, There has been a steady demand for drugs that activate AMPK as targets for metabolic diseases, cardiovascular diseases, inflammatory diseases, etc., which can be treated by exercise-like effects.

Thus, the present inventors have found that metabolic diseases such as hypertension, obesity and diabetes, heart disease and inflammatory diseases can be improved when the? 1-adrenergic receptor is activated, and as a result of intensive studies on its action mechanism, , It is possible to increase the expression of active -AMPK, PPAR-δ, and PGC-1α, and to induce exercise-like effects in the multi-passages such as skeletal muscle, myocardium and liver.

Accordingly, an object of the present invention is to provide a method for screening a drug for inducing exercise-like effects using an? 1-adrenergic receptor agonist, and a pharmaceutical composition for inducing exercise-like effects containing a drug screened by the above- .

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

 The present invention provides a method for screening a drug for inducing exercise-like effects using an? 1-adrenergic receptor agonist.

In one embodiment of the present invention, the screening method comprises the steps of: (a) treating the cell with an? 1 -adrenergic receptor agonist in vitro ; And (b) measuring the expression of AMP-activated protein kinase, PPAR-δ, or PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator-1α) .

In another embodiment of the present invention, the screening method comprises the step of (c) selecting a treatment-efficacy agent as a drug when the expression of the phosphorylated-AMPK, PPAR-δ or PGC-1α is increased as compared to the untreated group And further comprising:

In another embodiment of the present invention, the expression in step (b) is selected from the group consisting of Western blotting, antibody immunoprecipitation, ELISA, mass spectrometry, RT-PCR, competitive RT- (Real-time RT-PCR), RPA (RNase protection assay) or Northern blotting.

In another embodiment of the present invention, the cell in step (a) is a cell of a tissue selected from the group consisting of skeletal muscle, myocardium, liver, fat, and pancreas.

In another embodiment of the present invention, the exercise-like effect is a therapeutic effect of a disease selected from the group consisting of metabolic diseases, cardiovascular diseases and inflammatory diseases.

In another embodiment of the present invention, the metabolic disease is a disease selected from the group consisting of hypertension, hyperlipidemia, diabetes, obesity, arteriosclerosis and fatty liver.

The present invention also provides a pharmaceutical composition for inducing exercise-like effects, which comprises a drug screened by the above method as an active ingredient.

In one embodiment of the present invention, the drug is an? 1-adrenergic receptor agonist.

In another embodiment of the present invention, the alpha 1-adrenergic receptor agonist is characterized by being midodrine or a pharmaceutically acceptable salt thereof.

In another embodiment of the present invention, the exercise-like effect is a therapeutic effect of a disease selected from the group consisting of metabolic diseases, cardiovascular diseases and inflammatory diseases.

In another embodiment of the present invention, the metabolic disease is a disease selected from the group consisting of hypertension, hyperlipidemia, diabetes, obesity, arteriosclerosis and fatty liver.

According to the method of the present invention, drugs that cause exercise-like effects can be easily and accurately screened in vitro . Therefore, drugs screened by the present method can be used for the treatment of diseases (such as metabolic diseases, heart diseases and inflammatory diseases Lt; RTI ID = 0.0 > prevention / treatment < / RTI >

FIGS. 1A and 1B are graphs showing the effect of p-AMPK, which is an AMPK active (phosphorylated form), on the activation of α1-adrenergic receptor (α1-AR) by undidorin in rat skeletal muscle cell line L6 and mouse heart muscle cell line HL1, Western blot results show that protein expression is increased.
FIGS. 2A to 2C show results of measurement of diastolic / systolic blood pressure over three months in three groups of four-week old rats, and FIG. 2D shows the result of measurement of heart rate (blue: control group, red: , Green: atenolol treated group).
Figure 3A shows the protein expression status of alpha 1-AR in skeletal muscle of basal 4-week old control rats (I), midodrine administered rats (II), atenolol-administered rats (III) 3b to 3d show the result of Western blotting of the protein expression of AMPK-PPARδ-PGC1α in the myocardium, skeletal muscle and liver of the rat group, respectively.
FIG. 4A shows the results of aortic tissues of basal 4-week old rat (I), midodrine administered rat (II), atenolol-administered rat (III) , Northern blot results confirming mRNA expression levels of genes associated with vasoconstriction, nitric oxide production, oxidative stress, and inflammation, respectively.
FIG. 5 shows the results of SDH (succinate dehydrogenase) activity measurement in the skeletal muscle of basal 4-week old rat (I), midodrine-treated rat (II), atenolol-administered rat (III) to be.
Figure 6 shows ATP levels measured by ELISA in the myocardium, skeletal muscle and liver of basal 4-week old rat (I), midodrine administered rat (II), atenolol-administered rat (III) This is a result.

The present invention provides a screening method for drugs for inducing exercise-like effects using an? 1-adrenergic receptor agonist.

In the present invention, it has been found that the α1-AR agonists can exert additional exercise-like effects on the myocardial muscles, skeletal muscles, liver, and the like through not only the original effect of myocardial contraction enhanced by α1-AR stimulation but also AMPK activation .

Therefore, the screening method of the present invention can be used for the treatment of cells in vitro with an? 1 -adrenergic receptor agonist, and a method of screening a cell for inhibiting AMP-activated protein kinase, PPAR-δ (Peroxisome Proliferator Activated Receptor-? (Peroxisome proliferator-activated receptor Gamma Coactivator-1 alpha), and when the expression of the protein is increased as compared with the group not treated with the agonist, it can be achieved by selecting a treatment agonist as a drug.

In the method of the present invention, the α1-adrenergic receptor agonist is not particularly limited as long as it acts on the α1-adrenergic receptor to activate it. There are three types of adrenergic receptors, namely, alpha 1, alpha 2 and beta. In the present invention, it is aimed to screen drugs that exhibit similar effects to the effects of exercise, among known compounds that act on? 1 type receptors.

In the method of the present invention, the expression of p-AMPK, PPAR-δ, and PGC-1α can be confirmed by measuring the level of protein or mRNA. For example, Western blotting, antibody immunoprecipitation, ELISA, or mass spectrometry can be used. There is no limitation on the method of measuring the level of mRNA. For example, RT PCR, competitive RT-PCR, real-time RT-PCR, RPA (RNase protection assay) or Northern blotting.

In the method of the present invention, the cell to be treated with the? 1-adrenergic receptor agonist is not limited, but may be, for example, cells of skeletal muscle, cardiac muscle, liver, fat or pancreatic tissue.

In the method of the present invention, exercise-like effects include exercise (exercise) effects such as improvement in cardiac function (increase in contractility), increase in insulin sensitivity of muscles and promotion of oxidative phosphorylation, decrease in hypertension, decrease in cholesterol, fat accumulation and weight loss, Means a physiological effect, and there is no particular limitation, and thereby it is possible to achieve therapeutic effects such as metabolic diseases, cardiovascular diseases, inflammatory diseases and the like.

In the method of the present invention, metabolic disease refers to a disease caused by metabolic abnormalities such as glucose, fat and protein. Examples of the metabolic disease include hypertension, hyperlipidemia, diabetes, obesity, arteriosclerosis and fatty liver have.

The present invention also provides a pharmaceutical composition for inducing exercise-like effects containing a drug screened by the above method as an active ingredient.

In the composition of the present invention, the drug is not particularly limited as long as it is an α1-adrenergic receptor agonist that acts on the α1-adrenergic receptor to activate it, but may be, for example, midodrine, its analogue or its pharmaceutically acceptable It can be a salt.

At this time, the undoped compound is sold under the trade names amatine, proamatine, gutron and the like, and its IUPAC name is (RS) -N- [2- (2,5- Phenyl) -2-hydroxyethyl] glycine amide ((RS) -N- [2- (2,5-dimethoxyphenyl) -2-hydroxyethyl] glycinamide.

[Chemical Formula 1]

Midodrine is a drug prodrug that changes into a target compound in vivo after administration. It is converted into desglymidodrine, which is an active metabolite after in vivo administration, to activate the? 1-adrenergic receptor, followed by AMPK activation And finally induce a motion-like effect through the motion-like effect.

In addition, the compound represented by Formula 1 may form a "pharmaceutically acceptable salt ". Suitable pharmaceutically acceptable salts are not particularly limited as they are commonly used in the art to which the present invention pertains, such as acid addition salts. Preferred pharmaceutically acceptable acid addition salts include, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, or bromic acid; But are not limited to, acetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, fumaric acid, maleic acid, malonic acid, phthalic acid, succinic acid, lactic acid, citric acid, citric acid, gluconic acid, tartaric acid, salicylic acid, malic acid, And organic acids such as malic acid, aspartic acid, and glutamic acid. Examples of organic bases that can be used in the production of the organic base addition salt include tris (hydroxymethyl) methylamine, dicyclohexylamine, and the like. Examples of amino acids that can be used in the production of amino acid addition bases include natural amino acids such as alanine and glycine.

A "pharmaceutical composition" in the present invention may further comprise components such as conventional therapeutically active ingredients, other adjuvants, pharmaceutically acceptable carriers and the like. The pharmaceutically acceptable carrier includes saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and the like.

The composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method.

It will be apparent to those skilled in the art that the term "dosage" in the present invention can be variously adjusted depending on the patient's body weight, age, sex, health condition, diet, number of administrations, administration method, excretion rate and severity of disease.

The term "individual" as used herein refers to a subject in need of treatment for a disease, and more specifically refers to a human or non-human primate, mouse, rat, dog, cat, It means mammals.

"Pharmaceutically effective amount" in the present invention means the amount and type of disease to be administered, the age and sex of the patient, sensitivity to the drug, administration time, administration route and rate of release, And can be easily determined by those skilled in the art in such an amount that the maximum effect can be obtained without any adverse effect considering all of the factors.

The composition of the present invention is not limited as long as it can reach the target tissues. For example, oral administration, arterial injection, intravenous injection, percutaneous injection, intranasal administration, transbronchial administration, or intramuscular administration. The daily dose is about 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, and is preferably administered once a day or divided into several times a day.

The composition according to the present invention can achieve exercise-like effects on skeletal muscle and cardiac muscle through AMPK activation and increased expression of PPAR? And PGC-1 ?, which can be effectively used for the treatment of various metabolic diseases, heart failure, .

In the present invention, it was confirmed that the α1-AR agonist enhances the cardiac function by increasing the expression of PPAR-δ and PGC-1α independently of activating AMPK by α1-AR stimulation, Increasing the shortening to 40-50% and improving the rate of both contraction and relaxation.

Thus, the < RTI ID = 0.0 > ai-AR < / RTI > agonist has been shown to mediate through a triple effect on the direct stimulation of cardiac contraction and its kinetic effect, as well as exercise-like AMPK- PPAR delta activation by alpha 1-AR stimulation in cardiac, By enhancing cardiac function through indirect effects, it is thought to contribute to improving exercise tolerance in vivo .

Thus, it has been shown that AMPK-PPARδ activation by the α1-AR stimulation results in a cardio-motor-like effect, and additionally an AMPK-independent cardioversion effect that activates other exercise-like programs such as increased PPARδ and PGC-1α expression This fact was first disclosed in the present invention.

Specifically, in the present invention, the effect of α1-AR stimulation on the expression of exercise-like genes in myocardial cells and skeletal muscle cells was analyzed, and spontaneous hypertensive rats (SHR), which is similar to human metabolic syndrome, Were used to compare the effects of cardiac, skeletal muscle, and liver in vivo .

In addition, the effect of α1-AR stimulation was evaluated in relation to cardiac function / size, blood pressure, inflammatory cytokine, reactive oxygen species level, adiponectin, ATP level, succinate dehydrogenase (SDH) enzyme activity, fat level, and angiotensin II AT- .

As a result, the spontaneous hypertensive rats (SHR), which are the metabolic syndrome of humans, continuously increase blood pressure in the early stage, but when α1-AR is stimulated by α1-AR agonist, AMPK, PPAR- δ, increased activation and expression of PGC-1α, and increased cardiac contractility without cardiac hypertrophy or additional blood pressure elevation.

In addition, inflammatory cytokines, ROS, and cholesterol levels were decreased in the blood during α1-AR stimulation, and the ratio of PPARδ and PGC-1α activation to AMPK stimulation in the myocardium was higher than that in skeletal muscle and liver. These results are associated with exercise-like AMPK-PPARδ activation, meaning that they are independent of the muscle contraction effect by α1-AR stimulation, and that pharmacologically stimulated myocardial contraction contributes to cardiac AMPK-PPARδ-PGC1α activation .

It has also been shown in the present invention that the? 1 -AR agonist is more effective than the other exercise-like effect medicaments (atenolol), since the? 1 -AR agonist has a dual effect of improving cardiac contractility, Other drugs exert only exercise-like effects without a direct contraction of cardiac muscle contraction. In addition, other exercise analogues are mixed with various drugs in order to enhance their functions. However, the α1-AR agonist has the advantage of simultaneously exhibiting such exercise effects in multiple manifolds as a single kind of substance.

In addition, in the present invention, it was revealed that the phosphorylated AMPK in the heart was different between the experimental groups, although the left ventricular ejection fraction was increased as compared to the athenolol-treated animals in the untreated rats. Although a-1 AR has a favorable effect on the heart, the degree of α-1 AR stimulation is likely to be important in the long term afterwards, suggesting that a highly sustained enhancement of cardiac α- , Leading to pathological remodeling of progressive fibrosis and reactivation of the bovine protein gene.

In addition, in the present invention, it has been shown that cardiac hypertrophy does not occur despite α1-AR stimulation, which appears to be due to the effect of AMPK on angiotensin II inhibition, stimulation autophagy and the like. Further, according to the present invention, the left ventricular mass was smaller in the group treated with undoprion than in the group treated with athenolol, which could be explained as the difference in cardiac ATI expression.

In addition, in the present invention, it was shown that long-term administration of unadorned alleviates the rise in blood pressure in SHR, similar to treatment with atelolol, and blood pressure is directly related to vasoconstriction of α1-AR stimulation and AMPK activation accompanied by α1- , It can be concluded that α1-AR stimulation is effective for hypotensive and cardiac function enhancement in early SHRs.

In addition, in the present invention, through in vitro and in vivo experiments, for the first time, regardless of muscle movement, it was first shown that α1-AR stimulation activates AMPK-PPAR-δ-PGC1α expression in skeletal muscle. It has been previously reported that this exercise-related gene expression is one of the adaptive responses to maintain endurance exercise.

In addition, in the present invention, AMPK-PPAR-δ-PGC1α activation is induced in the liver by decreasing the ROS level during α1-AR stimulation, exhibiting a systemic effect on metabolism / biochemical reaction / inflammation reaction and exhibiting total cholesterol, LDL-cholesterol, and HDL-cholesterol levels were significantly reduced.

Hereinafter, embodiments are described to help understand the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples.

[ Example ]

Example  1: Experimental method

1-1. sample

TRIzol® reagent was purchased from Invitrogen (CA, USA). Power cDNA synthesis kit and Maxime PCR PreMix kit were purchased from iNtRON Biotechnology (Seongnam-si, Gyeonggi-do, Korea). PREP ™ protein extraction solution and pre-stained protein size markers were purchased from iNtRON Biotechnology. Anti-AMPKa (whole form of alpha subunit), and anti-phospho-AMPKa (phosphorylated at Thr172) primary antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Anti-rabbit secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Clarity Western ECL Substrate kit was purchased from Bio-Rad (Hercules, CA, USA). X-ray films were purchased from Agfa (Mortsel, Belgium) and development and fixation kits were purchased from Kodak (Rochester, NY, USA). The rat adiponectin detection ELISA kit was purchased from Abcam (Cambridge, UK).

1-2. Skeletal muscle / myocardial cells On AMPK  About alpha 1 -AR stimuli in vitro  effect

In order to confirm whether α1-AR stimulation of muscles is related to exercise effects, in vitro experiments were performed to confirm the expression of AMPK, which is a representative protein that increases during exercise, and the expression of PPARδ and PGC-1 together with AMPK in skeletal muscle, , The following experiment was carried out in vivo .

1-3. Animal experiment

Spontaneously Hypertensive Rats (SHRs) are known to express hyperhidrosis most similar to human primary hypertension. SHR usually begins to rise at 4 to 6 weeks of age, and full-blown hypertension develops at 8 to 12 weeks of age. SHR is widely used in related studies as an animal model for primary hypertension, especially hypertension with cardiac lesions, because it is often accompanied by damage to hypertensive target organs such as cardiomyopathy, heart failure and renal failure.

Three-week-old spontaneous hypertensive rats (SHRs) were kept under standardized conditions (21 ° C, 41% to 62% humidity), subjected to regular day / night (10/14 hours) I was allowed to freely approach. All animal experiments were performed in accordance with Korea University animal science regulations (KUIACUC-2012-100). Experimental procedures and acceptance conditions were approved by Korea University Animal Experiment Committee.

After one week of adaptation, rats were assigned to one of four groups (6 rats per group) as follows: group I (baseline control, sacrifice at 4 weeks), group II III (atenolol administration for 4 weeks), and Group IV (control without drug administration for 4 weeks). Group I and Group IV gave standard feed (K-H4 pellet, Ssniff) without any medication, group II gave the same feed (0.2 mg / kg / d) (1 mg / kg / d) with atenolol.

Blood pressure was measured every 7 days by tail-cut body plethysmography using a Visitech BP2000 system (Visitech Systems Inc.).

Animals in Group I were euthanized at 4 weeks of age, while rats of other groups were prescribed for 4 weeks and then euthanized at 8 weeks of age. Blood samples were taken from the inferior vein and the heart, aorta, liver, skeletal muscle, and visceral fat were cleanly incised and weighed. Collected organs were stored in -80 ° C refrigerator or 10% formalin for immersion fixation.

1-4. Echocardiographic record of heart echocardiographic ) Inspection

After intramuscular anesthesia with Zoletil® (8 mg / kg) and xylzine (2 mg / kg), M-mode echocardiograms were obtained by laying the rats on the left side. All tests were performed using Vivid 7 (GE Medical Systems, Milwaukee, WI, USA) with a 12 MHz transducer. After obtaining optimal two-dimensional shortening images for the left ventricle at the papillary muscle level, the M-mode tracing was simultaneously recorded at a rate of 100 mm / s while performing electrocardiographic recording. Heart wall thickness, volume, and mass were measured using a modified method of the American Society for Echocardiography method from at least three consecutive cardiac cycles for M-mode tracing.

1-5. Blood biochemistry, inflammation Marker , activation Oxygen species , ATP and Adiponectin  Measure

Enzymes (Roche Diagnostics GmbH; Mannheim, Germany) were used to measure total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations. 4-plex cytokine Milliplex panel (Millipore Corporation, Tokyo, Japan) was used for cytokines (interleukin (IL) -1α, IL-1β, IL-6, IL-4, IL- Billerica, MA, USA) was used to perform serum analysis of inflammatory markers. Acquisition was performed on a Luminex 100 platform and data were analyzed using a Multiplex analyzer. Active oxygen species and adiponectin were measured using an ELISA kit (MBS 815494, Mybiosource). The measured blood adiponectin levels were corrected for visceral fat weight (g).

1-6. ATP of tissue and ROS  ELISA method for measurement

0.02 g of liver tissue was homogenized in 500 [mu] l of PBS. After centrifugation of the homogenate at 1500 x g (or 5000 rpm) for 15 minutes, measurements were taken on the supernatant. 100 [mu] l of reference material or samples was poured into the appropriate wells in the antibody pre-coated microtiter plate and then 10 [mu] l of the remaining solution was added to the sample. 50 [mu] l of conjugate was added to each well and mixed, and the plate with the cover was incubated at 37 [deg.] C for 1 hour. 50 [mu] l of each of Substrates A and B were added to each well and incubated at 37 [deg.] C for 15 minutes. After the stop solution was added to each well, the optical density was measured at 450 nm using a microplate reader.

1-7. SDH of skeletal muscle ( succinate dehydrogenase ) Method for measuring enzyme activity

10 μl of the protease inhibitor cocktail was added to 1 ml of PBS solution per well and 500 μl of the solution was added to each well. 25 μl of 1 M phosphate buffer solution (25 μl) and 25 μl of 0.2 M sodium succinate × 25 μl of 3125 μl , NBT 25 μl × 25 = 625 μl, and DW 235 μl × 25 = 5875 μl were prepared and incubated at 37 ° C for 20 minutes before the reaction. To 0.02g of skeletal muscle tissue, 500μl of the PBS prepared above was added, and the plate was shredded for a short period of time, and the temperature was raised so that the enzyme was not destroyed. After centrifugation at 13000 rpm, 4 < 0 > C for 5 minutes, supernatant was obtained and transferred to a new tube. 410 μl of the culture solution was placed in a tube in advance, and 90 μl of a sample was added to the plate to allow the enzyme to stand. 410 μl of D. W was added to another tube, 90 μl of a sample was added, and the absorbance of the diluted solution was measured. The tubes and other tubes prepared above were placed in a 37 ° C water bath and reacted for 30 minutes. After the reaction was completed by inserting tubes into ice, 200 μl of each tube was dispensed into 96 well plates and the absorbance was measured at 550 nm , And the enzyme activity of succinic acid dehydrogenase (SDH) was calculated by applying the results to the following equation.

Enzyme activity = (enzyme reaction absorbance value - enzyme solution dilution liquid absorbance value) / protein quantification value (Bradford 595 nm)

1-8. Aorta and heart mRNA  For quantifying expression Reverse transcription  Polymerase chain reaction (RT-PCR)

Total RNA was extracted using TriZol reagent according to the manufacturer's instructions. The complementary DNA was synthesized from full-length RNA using the Power cDNA Synthesis kit and was transformed into an angiotensin II type I receptor (AT1R), endothelial nitric oxide synthase (eNOS), superoxide dismutase (SOD), gp91- phox (NADPH) , Tumor necrosis factor-alpha (TNF-a), and GAPDH were performed using a PCR Premix kit.

1-9. Western Blat

Protein content of protein extracts was measured using the Bradford method. The extracted proteins (20-30 [mu] g) were loaded onto a 10% SDS-PAGE gel. Western blot analysis was performed using primary antibodies against AMPKa, phosphorylated AMPKa, PPAR [delta] and PGC-l [alpha]. Images were obtained manually using a Kodak GBX developer and fixing reagents.

1-10. Statistical analysis

In the case of blood pressure, the entire blood pressure records obtained were analyzed (measurements on three animal groups from four to eight weeks of age). Blood pressure values were compared using ANOVA and p values <0.05 were considered significant. Continuous variables were recorded as mean ± standard deviation (SD). The overall difference values of the variables across the four groups were analyzed using the Kruskal-Wallis test. Differences between the two groups were evaluated using the Mann-Whitney U-test. P - values less than 0.05 were considered statistically significant. All statistical analyzes were performed using SPSS (ver. 20.0; SPSS Inc., Chicago, IL, USA).

Example  2: Experimental results

2-1. Skeletal muscle / myocardial cells alpha 1 During AR stimulation AMPK's  For phosphorylation in vitro effect

The α1-AR (α1- adrenoceptor) α1-AR agonist shown gave a stimulating effect on the rat skeletal muscle cell line (L6) and mouse cardiac cell line (HL1) in order to check the in vitro for AMPK and AMPK phosphorylation (activation) Respectively.

As a result, as shown in Figs. 1A and 1B, AMPK of skeletal muscle cells was expressed by? 1-AR stimulation, and phosphorylated AMPK expression was increased according to the concentration of undopyridine, . In addition, the α1-AR stimulation induced by the unadorned administration showed the same pattern of AMPK expression and phosphorylation in the myocardial cells in addition to the skeletal muscle.

Therefore, since changes in the action of AMPK (AMPK activation) in the skeletal muscle are simultaneously accompanied by enhancement of myocardial contractility (activation of AMPK + increase of myocardial contraction) in the myocardium, an additional myocardial exercise effect It can be seen. In other words, although it is known that the contraction force of myocardial cells is simply increased by the in vitro test, the increase in AMPK and phosphorylation in the skeletal muscle and cardiac myocyte are expected to be related to the exercise effect.

2-2. in vivo In animal models for heart function / weight / blood pressure alpha 1 -AR Efficacy agent  Administration effect

When gave shown administered in vivo If AMPK, PPAR-δ, and PGC-1α are also increased in the skeletal muscle, it can be considered that AMPK-PPARδ-PGC1α coexpression cascade that has already proven the exercise effect on the skeletal muscle affects the improvement of myocardial contractility. The in vitro effect of Example 2-1 was further investigated in vivo for cardiac function, body weight and blood pressure.

Heart function / weight

As shown in Table 1 below, the echocardiographic data of 8-week-old rats showed that the left ventricular performance of the untreated rat group II and the atenolol-treated rat group III was higher than the corresponding value of the control group IV.

In addition, the left ventricular mass was lowest in group II, but no significant difference in cardiac mass was observed between groups, and group III showed the highest weight.

[Table 1]

Blood pressure / heart rate

The diastolic / systolic blood pressure was measured over a month in three groups of 4-week old rats (blue: control group, red: midodrine group, green: athenolol group).

As a result, as shown in Figs. 2A to 2C, both diastolic and systolic blood pressures started to increase in spontaneously hypertensive rats (SHRs; control group) from 4 weeks of age, while the medodorally administered group II and the atenolol administered group III were increased After the week, both diastolic / systolic blood pressure decreased, and this effect continued until the end of the study period. Both Group II and Group III dilatation and systolic blood pressure were lower (p <0.05) than control (SHRs) blood pressure from Week 2 to Week 4 of the experiment.

In addition, as shown in Fig. 2 (d), heart rate was lowest in the athenolol group at the end of the experiment.

2-3. Myocardium, skeletal muscle, aorta, liver AMPK , PPAR -δ, PGC - 1α  Protein expression

In order to confirm the presence of α1-AR in skeletal muscle, α1-AR was detected in the skeletal muscle of basal 4-week control rats (I), midodrine administered rats (II), atenolol-administered rats (III) As a result of Western blotting of the protein expression status of -AR, α1-AR showed the highest expression in group IV as shown in FIG.

The expression levels of AMPK, PPAR-δ and PGC-1α protein in myocardium, skeletal muscle and liver were confirmed by Western blotting, respectively. As a result, as shown in FIG. 3B (myocardium), FIG. 3C (skeletal muscle) Similarly, in the case of myocardium, the expression of phosphorylated AMPK protein was higher in group I than in group IV (p <0.05), while the non-doprin group II showed significantly higher AMPK expression in myocardial and skeletal muscle than in control group IV, Athenolol-treated group III did not exhibit higher AMPK protein expression in the corresponding organs compared to control group IV at the same age.

Unusual is that the increase in PGC-1α and PPAR-δ is much greater in cardiac muscle than in AMPK, but the increase in PGC-1α and PPAR-δ is much less in skeletal muscle than in AMPK. This is because the exercise effect of myocardium directly increases PGC-1α and PPAR-δ expression as well as AMPK activation, whereas the skeletal muscle does not exercise relatively much. Therefore, PGC-1α and PPAR-δ But does not increase.

2-4. Aorta and heart Angiotensin  II &lt; / RTI &gt; AT-1 receptor, eNOS , SOD, NADPH , TNF?, MCP gene expression

In the aortic and myocardial tissues, vasoconstriction, nitrogen monoxide production (IGF-I) production was measured for basal 4-week old rat (I), midodrine-treated rat (II), atenolol- , Oxidative stress, and inflammation were identified by Northern blot analysis.

As a result, as shown in Fig. 4A, in the aorta, angiotensin II AT1R mRNA expression was lower in Groups II and III than in the two control groups (Groups I and IV). In addition, eNOS expression was lowest in group II, but no significant difference was observed with other groups, whereas SOD expression was highest in group II. The expression of gp91-phox (Nox-2) mRNA of NAD (P) H oxydase was higher in Group I but not in 8-week-old spontaneously hypertensive rats, regardless of drug administration. Expression of TNFα was lowest in group II, intermediate in group III, higher in group IV, and highest in group I.

In addition, as shown in Fig. 4B, the angiotensin II AT1R mRNA expression was lowest in group II and intermediate in group III, similar to the results of the aorta. eNOS expression was not different between the groups, and SOD was expressed at a significantly higher level in group II than in group IV. In contrast to aortic (vascular) tissue, gp91-phox (Nox-2) mRNA expression of NAD (P) H oxidase was not different between groups regardless of drug administration. Myocardial expression of TNFa did not decrease in response to the administration of midodrine.

2-5. Cytokine, active Oxygen species , Adiponectin , On fat profile alpha 1 -AR effect of administration of agonists

(IL, TNF?), Reactive oxygen species (ROS), adiponectin expression and lipid profile, and the results are shown in Table 2 below.

 [Table 2]

As shown in Table 2 above, the levels of proinflammatory cytokines (IL-1 [beta] and IL-6) were not significantly different between the groups, and the levels of IL-l [alpha] III and TNF-a expression was also significantly elevated in Group III than in the other groups, and IL-4 and IL-10 were slightly higher in Group III compared to the other groups.

In addition, the levels of reactive oxygen species (ROS) were lower in the midodrine administered group II than in the atenolol administered group III and the non-administered 8 week control group IV, but this difference was not statistically significant.

In addition, the level of adiponectin, which is the upstream molecule of AMPK, was measured to confirm how the α1-AR stimulation activates AMPK. As a result, Group II showed significantly higher serum adiponectin levels per visceral fat weight than group IV.

With respect to the fat profile, total cholesterol, LDL cholesterol, and HDL cholesterol were higher in the control group (Groups I and IV) than in the drug-treated group (Groups II and IV) There was no difference between the two.

[Table 3]

As shown in FIG. 5, the activity of succinate dehydrogenase (SDH) enzyme, which is a TCA circuit factor, was measured in skeletal muscle, and it was found to be the highest in the group II of the untreated control group (p <0.01).

2-6. Comparison of tissue ATP levels

ATP levels in heart, skeletal muscle, and liver were measured by ELISA method for basal 4-week-old rats (I), midodrine-treated rats (II), athenolol-administered rats (III) Respectively.

As a result, as shown in Fig. 6, ATP levels were higher in the cardiac tissues of the undoped or athenolol-treated group than the levels of the control SHRs despite the higher shrinking activity of the heart.

According to the above results, the? 1-AR stimulation by the? 1 -AR agonist causes a beneficial change in exercise-like effect on the skeletal muscle, liver and blood vessels without exercise, and the left ventricular outflow Improve the count, reduce inflammation, and alter biochemical responses during early hypertension in the early life of spontaneously hypertensive rats. It is associated with directly stimulated cardiac muscle contraction, cardiac movement-like effects, and AMPK activation.

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

Claims (12)

A method for screening a drug for inducing exercise-like effects using an? 1-adrenergic receptor agonist comprising the steps of:
(a) treating the cell with an? 1-adrenergic receptor agonist in vitro ;
(b) measuring the expression of AMP-activated protein kinase (PPAR-δ) and peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α); And
(c) when the expression of the phosphorylated-AMPK, PPAR-δ and PGC-1α is increased as compared with the group not treated with the agonist, the step of selecting the treatment agonist as a drug. delete delete The method according to claim 1, wherein the expression in step (b) is selected from the group consisting of Western blotting, antibody immunoprecipitation, ELISA, mass spectrometry, RT-PCR, competitive RT- time RT-PCR), RPA (RNase protection assay) or Northern blotting. The screening method according to claim 1, wherein the cell in step (a) is a cell of a tissue selected from the group consisting of skeletal muscle, myocardium, liver, fat and pancreas. The screening method according to claim 1, wherein the exercise-like effect is a therapeutic effect of a disease selected from the group consisting of metabolic diseases, cardiovascular diseases and inflammatory diseases. The screening method according to claim 6, wherein the metabolic disease is a disease selected from the group consisting of hypertension, hyperlipidemia, diabetes, obesity, arteriosclerosis and fatty liver. delete delete delete delete delete

Images